Abstract
Nomifensine, a tetrahydroisoquinoline antidepressant which facilitates dopaminergic and noradrenergic transmission, was studied in 28 Parkinsonism patients most of whom were also receiving conventional medications. Double-blind evaluations revealed a moderate therapeutic action at a mean dose level of 150 mg daily. Adverse reactions were encountered, similar to those induced by levodopa.
Cite
CITATION STYLE
APA
Teychenne, P. F., Park, D. M., Findley, L. J., Rose, F. C., & Calne, D. B. (1976). Nomifensine in Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 39(12), 1219–1221. https://doi.org/10.1136/jnnp.39.12.1219
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free